Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 945-924-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Skin sensitisation (OECD 442C and 442D): negative
Skin sensitisation (OECD 442E): positive
WoE conclusion from in vitro skin sensitisation battery: not skin sensitising
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 09 -18 Mar 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Version / remarks:
- 2015
- Deviations:
- yes
- Remarks:
- No information on stability, precision and co-elution controls provided. No information on stability/solubility of test substance after preparation of peptide depletion samples and after 22 h incubation.
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- THE DEPARTMENT OF HEALTH OF THE GOVERNMENT OF THE UNITED KINGDOM, UK
- Type of study:
- direct peptide reactivity assay (DPRA)
- Details on the study design:
- TEST METHOD
The DPRA is an in chemico test system proposed to address the molecular initiating event of the skin sensitisation adverse outcome pathway, namely protein reactivity, by substance towards model synthetic peptides containing either lysine or cysteine. The DPRA quantifies the free concentration of cysteine- or lysine-containing peptide following incubation with the test substance. Relative peptide concentration is measured by HPLC with gradient elution and UV detection at 220 nm. Cysteine- and lysine peptide percent depletion values are then calculated and used in the prediction model which allows assigning the test substance to one of four reactivity classes used to support the discrimination between sensitisers and non-sensitisers.
TEST SYSTEM
- Supplier: AnaSpec
- Synthetic cysteine-containing peptide:
Alternative name: Ac-RFAACAA-OH
Batch number: 1556171
Molecular weight: 751.5 g/L
Purity: 95%
Expiry date: 5 years
- Synthetic lysine-containing peptide:
Alternative name: Ac-RFAAKAA-OH
Batch number: 1556172
Molecular weight: 776 g/L
Purity: 90 - 95%
Expiry date: 5 years
SOLVENT CONTROL AND ASSESSMENT OF TEST ITEM SOLUBILITY
- Solvent: acetonitrile
The solubility of the test item in acetonitrile was assessed at a concentration of 100 mM.
POSITIVE CONTROL
- Substance: cinnamic aldehyde
- Batch number: MKBR2427V
- Purity: >95%
- Expiry date: Feb 2019
The positive control was prepared at a concentration of 100 mM.
STABILITY AND PRECISION CONTROL
Stability and precision controls of both peptides were prepared at a concentration of 0.5 mM.
PEPTIDE STOCK SOLUTION PREPARATION
Cysteine-containing peptide:
- Solvent: phosphate buffer (pH 7.5)
- Concentration: 0.667 mM
Lysine-containing peptide:
- Solvent: ammonium acetate buffer (pH 10.2)
- Concentration: 0.667 mM
INCUBATION CONDITIONS OF THE TEST SUBSTANCE WITH THE PEPTIDE SOLUTIONS
- Peptide to test substance ratios: Cysteine-containing peptide: 1:10 (0.5 mM peptide, 5 mM test substance/positive control); Lysine-containing peptide: 1:50 (0.5 mM peptide, 25 mM test substance/positive control)
- Temperature used during treatment / exposure: 25 °C
- Duration of treatment / exposure: at least 22 h prior to initiation of the analysis run
NUMBER OF REPLICATES
for each peptide in triplicates for treatment and control
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
- Specification of the device: Waters Alliance 2695 separation module and 2487 dual wavelength detector
- Column: Agilent Zorbax SB C18, 3.5 µm, 100 x 2.1 mm with guard column Phenomenex AJO4286
- HPLC mobile phase:
A: 0.1% (v/v) trifluoracetic acid in deionised water
B: 0.085% (v/v) trifluoracetic acid in acetonitrile
- Flow: 0.35 mL/min
- Gradient:
Time (min): 0, 20, 21, 23, 23.5, 30
% B: 10, 25, 90, 90, 10, 10
- Detector Wavelength: 220 nm
- Calibration standard concentrations of both peptides: 0.0167, 0.0334, 0.0667, 0.133, 0.267 and 0.534 mM
- Column temperature: 30 °C - Key result
- Run / experiment:
- other: ≥ 22 h incubation
- Parameter:
- other: % depletion of cysteine-containing peptide
- Remarks:
- (mean value of 3 replicates)
- Value:
- 0.906 %
- Vehicle controls validity:
- valid
- Negative controls validity:
- not specified
- Positive controls validity:
- valid
- Key result
- Run / experiment:
- other: ≥ 22 h incubation
- Parameter:
- other: % depletion of lysine-containing peptide
- Remarks:
- (mean value of 3 replicates)
- Value:
- -1.68 %
- Vehicle controls validity:
- valid
- Negative controls validity:
- not specified
- Positive controls validity:
- valid
- Key result
- Run / experiment:
- other: ≥ 22 h incubation
- Parameter:
- other: % overall mean depletion
- Value:
- 0.453 %
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- not applicable
- Other effects / acceptance of results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Other confounding effects: No co-elution of the test substance occurred during the assay. The solubility of the test substance in acetonitrile at a nominal concentration of 100 mM was confirmed.
ACCEPTANCE OF RESULTS:
All analytical acceptance criteria for each peptide were met. - Interpretation of results:
- other: DPRA prediction: negative (no or minimal reactivity) according to OECD 442C
- Conclusions:
- Under the conditions of the Direct Peptide Reactivity Assay the test substance showed no or minimal peptide reactivity.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 5 Sept - 10 Oct 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)
- Version / remarks:
- adopted 4 Feb 2015
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Schwabach, Germany
- Type of study:
- activation of keratinocytes
- Details on the study design:
- TEST METHOD
The in vitro KeratinoSens™ assay enables detection of the sensitising potential of a test substance by addressing the second molecular key event of the Adverse Outcome Pathway (AOP), namely activation of keratinocytes, by quantifying the luciferase activity in the transgenic cell line KeratinoSens™. The luciferase activity, assessed by luminescence measurement, compared to the respective solvent controls is used to support discrimination between skin sensitiser and non-sensitisers.
TEST CELL LINE
- Type: KeratinoSens™
- Source: Givaudan, Switzerland
- Passage number: 9 (Experiment 1), 12 (Experiment 2)
CELL CULTURE CONDITIONS
- Type and identity of media:
Maintenance medium: Dulbecco’s Modified Eagle Medium (GlutaMAX™) supplemented with 1.0 g/L D-glucose and Na-pyruvate, 10% fetal bovine calf serum and 1% geneticin (final concentration 500 µg/mL)
Assay medium: Dulbecco’s Modified Eagle Medium (GlutaMAX™) supplemented with 1.0 g/L D-glucose and Na-pyruvate and 10% fetal bovine calf serum
Test substance exposure medium: Dulbecco’s Modified Eagle Medium (GlutaMAX™) supplemented with 1.0 g/L D-glucose and Na-Pyruvate and 1% fetal bovine calf serum
- Temperature (°C): 37 ± 1.0
- CO2 (%): 5.0
TEST CONCENTRATIONS
0.98, 1.95, 3.91, 7.81, 15.63, 31.25, 61.5, 125, 250, 500, 1000 and 2000 µM
CONTROLS
Solvent control:
- Substance: dimethyl sulfoxide (DMSO)
- Final concentration: 1% (v/v)
Positive control:
- Substance: cinnamic aldehyde
- Final concentration: 4 - 64 µM
EXPOSURE CONDITIONS
- Exposure duration: 48 ± 1 h
NUMBER OF REPLICATIONS: triplicates (test substance and positive control) or sextuplicates (solvent control) in two independent experiments
DETERMINATION OF CELL VIABILITY
- Method: MTT assay
- MTT concentration: 5 mg/mL
- Incubation time: 4 h
- Device: plate reader
- Wavelength: 600 nm
DETERMINATION OF LUMINESCENCE
- Cell lysis reagent: Luciferase Cell Culture Lysis 5x Reagent Kit (Promega, Cat. No. E1531, Lot No. 0000199324)
- Device: plate reader - Key result
- Run / experiment:
- other: Experiment 1
- Parameter:
- other: maximum luciferase activity induction (Imax)
- Value:
- 0.98
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- other: test item concentration: 1000 µM; cell viability: 105.1%
- Key result
- Run / experiment:
- other: Experiment 2
- Parameter:
- other: maximum luciferase activity induction (Imax)
- Value:
- 1.22
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- other: test item concentration: 250 and 500 µM; cell viability: 111.4 and 109.7%
- Other effects / acceptance of results:
- ADDITIONAL INFORMATION ON CYTOTOXICITY: Clear evidence of cytotoxicity (cell viability < 70%) was observed at 2000 µM.
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for vehicle control: The average coefficient of variation of the luminescence reading for the vehicle control was < 20% (7.6% in and 10.5% in Experiment 1 and 2, respectively).
- Acceptance criteria met for positive control: The luciferase activity induced by the positive control at a concentration of 64 µM was between 2 and 8 (4.61 and 2.12 in Experiment 1 and 2, respectively) and the calculated EC1.5 value was between 7 and 30 µM (18.81 and 27.06 µM in Experiment 1 and 2, respectively). - Interpretation of results:
- other: activation of keratinocytes negativ according to OECD 442D
- Conclusions:
- Under the conditions of the ARE-Nrf2 Luciferase test the test substance did not induce luciferase activity in the transgenic KeratinoSens™ cell line.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 07 Mar - 10 Nov 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: Draft OECD Guideline 442E (In Vitro Skin Sensitisation: human Cell Line Activation Test (h-CLAT))
- Version / remarks:
- December 2015
- Deviations:
- yes
- Remarks:
- Cytotoxicity measurement and estimation of the CV75 value was performed by XTT test instead of flow cytometry.
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Hess. Ministerium für Umwelt, Klimaschutz, Landwirtschaft und Verbraucherschutz, Wiesbaden, Germany
- Type of study:
- activation of dendritic cells
- Details on the study design:
- TEST CELL LINE
- Strain: THP-1 cells (human monocytic leukemia cell line)
- Source: American Type Culture Collection
- Passage number: 5 and 7 (XTT test); 9, 10 and 21 (h-CLAT)
CELL CULTURE CONDITIONS
- Type and identity of media: RPMI-1640 supplemented with 10% (v/v) FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.05 mM 2-mercaptoethanol, 4.5 g/L glucose, 1% (v/v) sodium pyruvate and 1% (v/v) L-glutamine
- Temperature (°C): 37 ± 1.5
- CO2 (%): 5.0 ± 0.5
DOSE FINDING ASSAY BY CYTOTOXICITY MEASUREMENT (XTT TEST)
The doses investigated in the main experiment (h-CLAT) were determined with a XTT test. The XTT test is a method to investigate the cytotoxicity of a test substance. The test is based on the cleavage of the yellow tetrazolium salt, sodium 3'-(1-phenylaminocarbonyl)-(3,4-tetrazolium)-bis-(4–methoxy-6-nitro)-benzenesulfonic acid hydrate (XTT), to form an orange water soluble formazan dye by dehydrogenase activity in active mitochondria. Two independent cytotoxicity experiments were performed with different cell cultures or on different days to obtain a reliable concentration showing 75% cell viability (CV75).
CONTROLS
Negative control
- Substance: culture medium
Solvent control
- Substance: dimethyl sulfoxide (DMSO)
- Concentration: 0.2 - 0.5%
EXPOSURE CONDITIONS
- Exposure duration: 24 ± 1 h
TEST CONCENTRATIONS
- Justification for top concentration: The test substance was soluble in DMSO up to and including 250 µg/mL as tested by a solubility test.
1.91, 3.83, 7.66, 15.32, 30.64, 61.28, 122.55, 245.10 µg/mL (XTT 1); 1.95, 3.91, 7.81, 15.63, 31.25, 62.5, 125 and 250 µg/mL (XTT 2)
NUMBER OF REPLICATIONS: quadruplicates per concentration in two independent experiments
MEASUREMENT
- Device: microplate reader (Versamax Molecular Devices)
- Wavelength: 450 nm
- Reference wavelength: 690 nm
EVALUATION CRITERIA
A decrease in number of living cells results in a decrease in the overall activity of mitochondrial dehydrogenases in the sample. This decrease directly correlates to the amount of orange formazan formed, as monitored by the absorbance. The relative absorbance as compared to the solvent control is calculated using the formula:
Relative absorbance = 100 x [(mean absorbance test substance) - (absorbance blank)] / [(mean absorbance solvent control) - (absorbance blank)]
To calculate the concentration of test substance needed to reduce the relative absorbance to 75% of the solvent control (CV75) the following formula is used:
CV75 = Conc. > 75 - ([(Conc. > 75) - (Conc. < 75)] x [(% > 75) - 75] / [(% > 75) - (% < 75)])
a) Conc. > 75: max. measured concentration with the % of solvent control > 75%
b) Conc. < 75: min. measured concentration with the % of solvent control < 75%
c) % > 75: relative absorbance at a) in %
d) % < 75: relative absorbance at b) in %
ACCEPTANCE CRITERIA
The XTT test is considered to be acceptable if it meets the following criteria:
- mean absorbance of the negative control is ≥ 0.5
- mean viability of the solvent control is ≥ 70%
h-CLAT (main study)
The h-CLAT method is an in vitro method which quantifies changes of cell surface marker expression (CD86 and CD54) on a human cell line, THP-1 cells, following 24 h exposure to the test substance. The changes of surface marker expression are measured by flow cytometry following cell staining with fluorescein isothiocyanate (FITC)-labelled antibodies. The relative fluorescence intensity of surface markers compared to solvent control are calculated and used in the prediction model to support the discrimination between sensitisers and non-sensitisers.
CONTROLS
Negative Control
- Substance: culture medium
Solvent control
- Substance: dimethyl sulfoxide (DMSO)
- Concentration: 0.2%
Positive control
- Substance: 2,4-dinitrochlorobenzene (DNCB) in DMSO
- Concentration: 2 and 3 µg/mL
EXPOSURE CONDITIONS
- Exposure duration: 24 ± 25 min
TEST CONCENTRATIONS
- Justification for top dose: Due to a lack in toxicity in the XTT test, a CV75 could not be determined. Therefore, the highest soluble concentration (250 µg/mL) multiplied with 1.2 was prepared as highest concentration.
84, 100, 121, 145, 174, 208, 250 and 300 µg/mL
NUMBER OF REPLICATIONS: at least in triplicates for the different stainings in three independent experiments
STAINING
- Antibodies: FITC anti-CD54 (Clone: Fun-1); FITC anti-CD86 (Clone: 6.5B5); FITC mouse IgG1 (isotype control)
- Temperature: 2 - 8 °C
- Duration: 30 ± 5 min
MEASUREMENT
- Device: flow cytometer FACSCalibur (Becton Dickinson)
EVALUATION CRITERIA
The relative fluorescence intensity (RFI) is used as an indicator of CD86 and CD54 expression, and is calculated as follows for each concentration:
RFI (%) = [(MFI of test substance treated cells) - (MFI of test substance isotype control cells) / (MFI of solvent control cells) - (MFI of solvent isotype control cells)] x 100
MFI: geometric mean fluorescence intensity (GeoMean)
The cell viability is calculated as follows for each concentration:
Cell viability (%) = (mean cytotox of solvent control cells) / (mean cytotox of test substance treated cells) x 100
Where the mean cytotox is the mean of GeoMean (7-AAD) isotype control, GeoMean (7-AAD) CD54 and GeoMean (7-AAD) CD86.
The test substance is tested in 2 independent runs. If the RFI of CD86 is ≥ 150% or if the RFI of CD54 is ≥ 200% in both independent run data, the test substance is considered to be a sensitizer. Otherwise it is considered to be a non-sensitizer. In case of different results in both runs, a third run has to be performed. If the RFI of CD86 is ≥ 150% at any dose in at least 2 of 3 independent run data, or if the RFI of CD54 is ≥ 200% in at least 2 of 3 independent run data, the test substance is considered to be a sensitizer. Otherwise it is considered to be a non-sensitizer.
ACCEPTANCE CRITERIA
The study is considered as valid, if the following criteria are met:
- Cell viability of negative control is adjusted to 100% and the cell viability of the solvent control should be more than 90% in comparison to the negative control.
- In the positive control, RFI values of both CD86 and CD54 should exceed the positive criteria (CD86 ≥ 150% and CD54 ≥ 200%) and the cell viability should be > 50%.
- In the vehicle control, RFI values compared to the negative control of both CD86 and CD54 should not exceed the positive criteria (CD86 ≥ 150% and CD54 ≥ 200%).
- For negative and solvent controls, the MFI ratio of CD86 and CD54 to isotype control should be > 105%.
- For the test substance resulting in negative outcome, the cell viability at the 1.2 × CV75 value should be less than 90%. If the cell viability at the 1.2 × CV75 value is more than 90% for a positive tested test substance, the data will be acceptable. If 5 mg/mL in saline, 1 mg/mL in DMSO or the highest soluble dose will be used as the maximal test concentration instead of CV75-based dose, the data for test substance are accepted independent by the cell viability.
- The cell viability of at least 4 doses in each experiment should be ≥50%. - Run / experiment:
- other: 24 h incubation
- Parameter:
- other: relative fluorescence intensity of CD86 (%)
- Value:
- 150
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: in 2 out of 3 independent run data
- Run / experiment:
- other: 24 h incubation
- Parameter:
- other: relative fluorescence intensity of CD54 (%)
- Value:
- 200
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: in 2 out of 3 independent run data
- Other effects / acceptance of results:
- ADDITIONAL INFORMATION ON CYTOTOXICITY:
XTT test
Cytotoxic effects were not observed following incubation with the test item up to the highest soluble concentration (250 µg/mL). The viability of the cells in both XTT spaced within a range of 92.67 to 112.4% and 81.35 to 108.61%, respectively. Due to the lack of cytotoxicity, a CV75 value could not be calculated.
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for solvent control: In the solvent control, RFI values of both CD86 and CD54 did not exceed the positive criteria (CD86 ≥ 150% and CD54 ≥ 200%) and did not induce cytotoxic effects.
- Acceptance criteria met for positive control: The RFI values of the positive control for CD86 and CD54 exceeded the positive criteria (CD86 > 150% and CD54 > 200%) and the cell viability was > 50%. - Interpretation of results:
- other: activation of dendritic cells positive according to OECD 442E
- Conclusions:
- Under the conditions of the Human Cell Line Activation Test the test substance increased the expression of CD86 and CD54, cell surface marker associated with the process of activation of monocytes and dendritic cells. Based on this result, the h-CLAT prediction is considered positive for skin sensitisation.
Referenceopen allclose all
Table 5. Mean peptide depletion of cysteine-containing peptide.
|
Peak area (µV.sec) |
Peptide concentration (µg/mL)* |
Peptide depletion (%)** |
Mean depletion ± CV (%) |
Test substance |
902257 |
381 |
0.608 |
0.906 ± 0.28 |
899025 |
379 |
0.964 |
||
897389 |
378 |
01.15 |
||
Positive control |
244716 |
103 |
73.0 |
73.0 ± 0.35 |
245752 |
104 |
72.9 |
||
244042 |
103 |
73.1 |
*: Samples prepared at a concentration of 376 μg/mL (0.5 mM)
**: Calculated against a mean reference control peak area of 940000 μV.sec (n=6)
Table 6. Mean peptide depletion of lysine-containing peptide.
|
Peak area (µV.sec) |
Peptide concentration (µg/mL)* |
Peptide depletion (%)** |
Mean depletion ± CV (%) |
Test substance |
792447 |
410 |
-3.34 |
-1.68 ± 1.81 |
782216 |
405 |
-2.00 |
||
764584 |
396 |
0.295 |
||
Positive control |
337396 |
175 |
56.0 |
56.3 ± 1.54 |
338682 |
176 |
55.8 |
||
329160 |
171 |
57.1 |
*: Samples prepared at a concentration of 388 μg/mL (0.5 mM)
**: Calculated against a mean control peak area of 766850 μV.sec (n=6)
Table1. Results of the cytotoxicity measurement
|
Concentration [µM] |
Cell Viability (%) |
||
Experiment 1 |
Experiment 2 |
Mean ± SD |
||
Vehicle control |
- |
100 |
100 |
100 ± 0.0 |
Positive control |
4 |
98.5 |
98.8 |
98.7 ± 0.2 |
8 |
106.0 |
109.0 |
107.5 ± 2.1 |
|
16 |
111.3 |
110.2 |
110.7 ± 0.8 |
|
32 |
122.4 |
111.3 |
116.9 ± 7.8 |
|
64 |
126.8 |
125.1 |
125.9 ± 1.2 |
|
Test substance |
0.98 |
102.6 |
106.1 |
104.4 ± 2.5 |
1.95 |
95.6 |
98.8 |
97.2 ± 2.3 |
|
3.91 |
98.7 |
100.3 |
99.5 ± 1.1 |
|
7.81 |
95.2 |
90.4 |
92.8 ± 3.4 |
|
15.63 |
94.6 |
101.4 |
98.0 ± 4.7 |
|
31.25 |
90.3 |
109.5 |
99.5 ± 1.1 |
|
62.50 |
90.6 |
106.1 |
92.8 ± 3.4 |
|
125 |
92.9 |
107.3 |
100.1 ± 10.2 |
|
250 |
92.9 |
111.4 |
102.1 ± 13.1 |
|
500 |
92.7 |
109.7 |
101.2 ± 12.0 |
|
1000 |
105.1 |
111.8 |
108.4 ± 4.7 |
|
2000 |
0.1 |
-0.1 |
0.0 ± 0.1 |
Table 2. Induction of luciferase activity
|
Concentration [µM] |
Fold induction |
||
Experiment 1 |
Experiment 2 |
Mean ± SD |
||
Vehicle control |
- |
1.00 |
1.00 |
1.00 ± 0.00 |
Positive control |
4 |
1.08 |
1.10 |
1.09 ± 0.01 |
8 |
1.26 |
1.24 |
1.25 ± 0.02 |
|
16 |
1.31 |
1.29 |
1.30 ± 0.01 |
|
32 |
2.37 |
1.59 |
1.98 ± 0.55 |
|
64 |
4.61 |
2.12 |
3.37 ± 1.76 |
|
Test substance |
0.98 |
0.86 |
1.01 |
0.93 ± 0.11 |
1.95 |
0.86 |
1.13 |
1.00 ± 0.19 |
|
3.91 |
0.92 |
1.16 |
1.04 ± 0.17 |
|
7.81 |
0.88 |
1.13 |
1.01 ± 0.18 |
|
15.63 |
0.93 |
1.09 |
1.01 ± 0.12 |
|
31.25 |
0.84 |
1.08 |
0.96 ± 0.16 |
|
62.50 |
0.91 |
1.16 |
1.04 ± 0.18 |
|
125 |
0.91 |
1.21 |
1.06 ± 0.21 |
|
250 |
0.89 |
1.22 |
1.05 ± 0.24 |
|
500 |
0.91 |
1.22 |
1.06 ± 0.22 |
|
1000 |
0.98 |
1.14 |
1.06 ± 0.11 |
|
2000 |
0.00 |
0.00 |
0.00 ± 0.00 |
Table 1. Results of the first XTT Test
|
Concentration (µg/mL) # |
Mean absorbance* |
SD |
Blank |
Absorbance in % of vehicle control** |
Negative control |
|
0.741 |
0.056 |
0.249 |
114.31 |
Vehicle Control |
|
0.677 |
0.040 |
0.246 |
100.00 |
Test substance |
1.91 |
0.690 |
0.028 |
0.242 |
103.92 |
3.83 |
0.675 |
0.026 |
0.244 |
99.99 |
|
7.66 |
0.702 |
0.019 |
0.241 |
106.98 |
|
15.32 |
0.727 |
0.082 |
0.243 |
112.40 |
|
30.64 |
0.721 |
0.121 |
0.246 |
110.26 |
|
61.28 |
0.691 |
0.051 |
0.248 |
102.78 |
|
122.55 |
0.645 |
0.046 |
0.245 |
92.73 |
|
245.10 |
0.644 |
0.026 |
0.245 |
92.67 |
*: mean absorbance (absolute) of 4 wells
**: relative absorbance
#: The test item was formulated without adjustment to purity in the first dose finding assay (XTT Test). Therefore, the used test item concentrations were corrected to the purity of the test item with a correction factor of 1.02.
Table 2. Results of the second XTT Test
|
Concentration (µg/mL) |
Mean absorbance* |
SD |
Blank |
Absorbance in % of vehicle control** |
Negative control |
|
0.759 |
0.011 |
0.278 |
109.97 |
Vehicle Control |
|
0.718 |
0.054 |
0.281 |
100.00 |
Test substance |
1.95 |
0.715 |
0.035 |
0.277 |
100.18 |
3.91 |
0.705 |
0.049 |
0.279 |
97.30 |
|
7.81 |
0.709 |
0.105 |
0.274 |
99.26 |
|
15.63 |
0.651 |
0.054 |
0.272 |
86.59 |
|
31.25 |
0.634 |
0.042 |
0.278 |
81.35 |
|
62.5 |
0.677 |
0.042 |
0.280 |
90.78 |
|
125 |
0.719 |
0.035 |
0.278 |
100.82 |
|
250 |
0.756 |
0.051 |
0.281 |
108.61 |
*: mean absorbance (absolute) of 4 wells
**: relative absorbance
Table 3. Results of the first h-CLAT run
|
Concentration (µg/mL) |
Antibody / ISO |
MFI GeoMean(FITC) |
MFI-ISO |
Cyto(Geo) GeoMean(7-AAD) |
Mean Cyto |
RFI (%) |
Viability (%) |
Negative control |
- |
ISO |
2.11 |
|
1.94 |
1.8 |
|
100.0 |
CD54 |
2.58 |
0.47 |
2.12 |
100.0 |
||||
CD86 |
4.19 |
2.08 |
1.41 |
100.0 |
||||
Vehicle control |
- |
ISO |
2.07 |
|
1.67 |
1.7 |
|
100.0 |
CD54 |
2.69 |
0.62 |
2.00 |
100.0 |
||||
CD86 |
4.47 |
2.40 |
1.40 |
100.0 |
||||
Positive control |
2 |
ISO |
2.38 |
|
4.41 |
3.2 |
|
52.8 |
CD54 |
5.11 |
2.73 |
2.86 |
440.3* |
||||
CD86 |
7.55 |
5.17 |
2.34 |
215.4* |
||||
3 |
ISO |
2.35 |
|
3.24 |
2.6 |
|
65.0 |
|
CD54 |
7.22 |
4.87 |
2.30 |
785.5* |
||||
CD86 |
6.81 |
4.46 |
2.26 |
185.8* |
||||
Test substance |
84 |
ISO |
2.01 |
|
2.11 |
2.5 |
|
66.8 |
CD54 |
2.60 |
0.59 |
2.96 |
95.2 |
||||
CD86 |
3.25 |
1.24 |
2.52 |
51.7 |
||||
100 |
ISO |
2.05 |
|
2.01 |
2.3 |
|
75.0 |
|
CD54 |
2.65 |
0.60 |
2.62 |
96.8 |
||||
CD86 |
3.67 |
1.62 |
2.13 |
67.5 |
||||
121 |
ISO |
1.97 |
|
3.38 |
2.9 |
|
57.9 |
|
CD54 |
2.73 |
0.76 |
2.43 |
122.6 |
||||
CD86 |
3.65 |
1.68 |
2.95 |
70.0 |
||||
145 |
ISO |
1.98 |
|
3.85 |
2.5 |
|
69.0 |
|
CD54 |
2.76 |
0.78 |
1.94 |
125.8 |
||||
CD86 |
3.53 |
1.55 |
1.56 |
64.6 |
||||
174 |
ISO |
2.05 |
|
2.82 |
2.1 |
|
81.8 |
|
CD54 |
2.81 |
0.76 |
1.87 |
122.6 |
||||
CD86 |
3.74 |
1.69 |
1.51 |
70.4 |
||||
208 |
ISO |
2.04 |
|
2.68 |
2.1 |
|
82.4 |
|
CD54 |
2.82 |
0.78 |
2.00 |
125.8 |
||||
CD86 |
3.51 |
1.47 |
1.47 |
61.3 |
||||
250 |
ISO |
2.18 |
|
2.75 |
2.3 |
|
72.8 |
|
CD54 |
2.95 |
0.77 |
2.70 |
124.2 |
||||
CD86 |
3.82 |
1.64 |
1.51 |
68.3 |
||||
300PS |
ISO |
2.88 |
|
2.29 |
2.6 |
|
64.7 |
|
CD54 |
10.55 |
7.67 |
2.93 |
1237.1* |
||||
CD86 |
6.30 |
3.42 |
2.62 |
142.5 |
PSPhase separation (oily droplets)
*: RFI value of CD86 or CD54 exceeded the criteria for a positive response (CD86 ≥ 150% and CD54 ≥ 200%).
Table 4. Results of the second h-CLAT run
|
Concentration (µg/mL) |
Antibody / ISO |
MFI GeoMean(FITC) |
MFI-ISO |
Cyto(Geo) GeoMean(7-AAD) |
Mean Cyto |
RFI (%) |
Viability (%) |
Negative control |
- |
ISO |
2.02 |
|
2.07 |
1.9 |
|
100.0 |
CD54 |
2.78 |
0.76 |
1.88 |
100.0 |
||||
CD86 |
4.04 |
2.02 |
1.77 |
100.0 |
||||
Vehicle control |
- |
ISO |
2.32 |
|
1.92 |
2.0 |
|
100.0 |
CD54 |
2.96 |
0.64 |
2.24 |
100.0 |
||||
CD86 |
3.83 |
1.51 |
1.77 |
100.0 |
||||
Positive control |
2 |
ISO |
2.33 |
|
3.06 |
2.0 |
|
99.0 |
CD54 |
13.30 |
10.97 |
1.48 |
1714.1* |
||||
CD86 |
10.71 |
8.38 |
1.45 |
555.0* |
||||
3 |
ISO |
2.31 |
|
4.16 |
3.3 |
|
59.9 |
|
CD54 |
11.86 |
9.55 |
3.01 |
1492.2* |
||||
CD86 |
7.70 |
5.39 |
2.73 |
357.0* |
||||
Test substance |
84 |
ISO |
2.00 |
|
2.44 |
2.2 |
|
90.8 |
CD54 |
2.93 |
0.93 |
2.07 |
145.3 |
||||
CD86 |
3.57 |
1.57 |
2.02 |
104.0 |
||||
100 |
ISO |
2.01 |
|
2.60 |
2.3 |
|
85.7 |
|
CD54 |
3.02 |
1.01 |
2.51 |
157.8 |
||||
CD86 |
3.74 |
1.73 |
1.81 |
114.6 |
||||
121 |
ISO |
2.06 |
|
2.52 |
2.1 |
|
94.9 |
|
CD54 |
3.19 |
1.13 |
2.06 |
176.6 |
||||
CD86 |
4.58 |
2.52 |
1.67 |
166.9* |
||||
145 |
ISO |
2.02 |
|
2.67 |
2.3 |
|
84.5 |
|
CD54 |
3.02 |
1.00 |
2.42 |
156.3 |
||||
CD86 |
3.76 |
1.74 |
1.93 |
115.2 |
||||
174 |
ISO |
2.03 |
|
2.64 |
2.7 |
|
73.8 |
|
CD54 |
3.10 |
1.07 |
2.56 |
167.2 |
||||
CD86 |
3.68 |
1.65 |
2.83 |
109.3 |
||||
208 |
ISO |
2.07 |
|
2.41 |
2.3 |
|
86.6 |
|
CD54 |
3.26 |
1.19 |
2.03 |
185.9 |
||||
CD86 |
3.68 |
1.61 |
2.41 |
106.6 |
||||
250 |
ISO |
2.29 |
|
2.61 |
2.0 |
|
100.7 |
|
CD54 |
4.79 |
2.50 |
1.22 |
390.6* |
||||
CD86 |
4.20 |
1.91 |
2.06 |
126.5 |
||||
300PS |
ISO |
2.68 |
|
3.52 |
2.5 |
|
79.4 |
|
CD54 |
26.61 |
23.93 |
1.72 |
3739.1* |
||||
CD86 |
7.83 |
5.15 |
2.23 |
341.1* |
PSPhase separation (oily droplets)
*: RFI value of CD86 or CD54 exceeded the criteria for a positive response (CD86 ≥ 150% and CD54 ≥ 200%).
Table 5. Results of the third h-CLAT run
|
Concentration (µg/mL) |
Antibody / ISO |
MFI GeoMean(FITC) |
MFI-ISO |
Cyto(Geo) GeoMean(7-AAD) |
Mean Cyto |
RFI (%) |
Viability (%) |
Negative control |
- |
ISO |
2.17 |
|
3.09 |
3.1 |
|
100.0 |
CD54 |
2.99 |
0.82 |
2.90 |
100.0 |
||||
CD86 |
3.67 |
1.50 |
3.23 |
100.0 |
||||
Vehicle control |
- |
ISO |
2.12 |
|
3.02 |
2.9 |
|
100.0 |
CD54 |
3.03 |
0.91 |
2.77 |
100.0 |
||||
CD86 |
3.35 |
1.23 |
2.79 |
100.0 |
||||
Positive control |
2 |
ISO |
2.58 |
|
4.09 |
3.9 |
|
73.5 |
CD54 |
6.47 |
3.89 |
4.16 |
427.5* |
||||
CD86 |
6.31 |
3.73 |
3.43 |
303.3* |
||||
3 |
ISO |
2.87 |
|
4.64 |
3.9 |
|
72.6 |
|
CD54 |
7.34 |
4.47 |
3.64 |
491.2* |
||||
CD86 |
8.42 |
5.55 |
3.54 |
451.2* |
||||
Test substance |
84 |
ISO |
2.42 |
|
3.15 |
3.0 |
|
96.6 |
CD54 |
3.31 |
0.89 |
2.93 |
97.8 |
||||
CD86 |
3.37 |
0.95 |
2.80 |
77.2 |
||||
100 |
ISO |
2.48 |
|
3.06 |
2.9 |
|
97.7 |
|
CD54 |
3.34 |
0.86 |
2.88 |
94.5 |
||||
CD86 |
3.62 |
1.14 |
2.84 |
92.7 |
||||
121 |
ISO |
2.53 |
|
3.25 |
3.0 |
|
96.5 |
|
CD54 |
3.52 |
0.99 |
2.81 |
108.8 |
||||
CD86 |
3.89 |
1.36 |
2.83 |
110.6 |
||||
145 |
ISO |
2.69 |
|
3.40 |
3.2 |
|
90.0 |
|
CD54 |
4.02 |
1.33 |
3.10 |
146.2 |
||||
CD86 |
4.43 |
1.74 |
3.03 |
141.5 |
||||
174 |
ISO |
2.71 |
|
3.78 |
3.5 |
|
82.3 |
|
CD54 |
4.06 |
1.35 |
3.29 |
148.4 |
||||
CD86 |
4.40 |
1.69 |
3.36 |
137.4 |
||||
208 |
ISO |
2.87 |
|
3.96 |
3.6 |
|
78.4 |
|
CD54 |
4.94 |
2.07 |
3.58 |
227.5* |
||||
CD86 |
5.39 |
2.52 |
3.40 |
204.9* |
||||
250 |
ISO |
3.03 |
|
4.60 |
4.2 |
|
67.5 |
|
CD54 |
5.15 |
2.12 |
4.15 |
233.0* |
||||
CD86 |
6.49 |
3.46 |
3.97 |
281.3* |
||||
300PS |
ISO |
3.23 |
|
5.58 |
4.9 |
|
58.0 |
|
CD54 |
6.02 |
2.79 |
4.72 |
306.6* |
||||
CD86 |
8.71 |
5.48 |
4.49 |
445.5* |
PSPhase separation (oily droplets)
*: RFI value of CD86 or CD54 exceeded the criteria for a positive response (CD86 ≥ 150% and CD54 ≥ 200%).
Phase separation (oily droplets) was observed at the highest tested test item concentration (300 µg/mL) therefore this concentration was excluded from the evaluation. After exclusion of this concentration, the RFI of CD86 and CD54 was greater than 150% and 200%, respectively in at least one dose in 2 out of 3 independent run data.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The skin sensitizing potential of the test substance was evaluated in a combination of non-animal methods (in chemico and in vitro). Three key events of skin sensitisation a) molecular interaction with skin proteins, b) inflammatory response in keratinocytes and c) activation of dendritic cells were addressed.
a) Molecular interaction with skin proteins
The protein reactivity of the test substance was investigated in a Direct Peptide Reactivity Assay (DPRA) (2016) performed according to OECD Guideline 442C and in compliance with GLP. The test substance was dissolved in acetonitrile to prepare a 100 mM solution. The solubility in acetonitrile was confirmed. Stock solutions of cysteine and lysine containing synthetic peptides with a purity in the range of 90-95% were freshly prepared just before incubation with the test substance. The cysteine and lysine peptide solutions were incubated in HPLC vials with the test substance or the positive control cinnamic aldehyde at 1:10 (5 mM cysteine and 5 mM test substance/positive control) and 1:50 ratios (0.5 mM lysine and 25 mM test substance/positive control), respectively. After an incubation time for a minimum of 22 h at 25 °C in an HPLC autosampler, HPLC-UV analysis for the cysteine and lysine peptides were performed. All analytical acceptance criteria for each peptide run were met and the positive control proved the validity of the test. In presence of the test substance the mean depletion of cysteine and lysine peptide was 0.906% and -1.68%, respectively. The overall mean percent cysteine and lysine depletion is 0.453 and therefore the test substance is allocated to the “no or minimal reactivity” class (mean % depletion <6.38%) and considered to be negative for molecular interaction with skin proteins.
b) Activation of keratinocytes
The activation of keratinocytes of the test substance was investigated in an ARE-Nrf2 Luciferase Test (2016) in the transgenic KeratinoSens™ cell line according to OECD Guideline 442D and in compliance with GLP. Cells were incubated with test substance concentrations of 0.98, 1.95, 3.91, 7.81, 15.63, 31.25, 61.5, 125, 250, 500, 1000, 2000 µM in DMSO for 48 h at 37°C. After exposure cells were lysed and luciferase activity was assessed by luminescence measurement. The study was conducted in two independent experiments. In the first experiment a max luciferase activity (Imax) induction of 0.98 was determined at a test substance concentration of 1000 µM. The corresponding cell viability was 105.1%. In the second experiment a max luciferase activity (Imax) induction of 1.22 was determined at test substance concentrations of 250 and 500 mM. The corresponding cell viabilities were 111.4% and 109.7%. Therefore in both experiments no luciferase activity induction >1.5 was observed and no EC1.5 could be calculated. Cytotoxicity (cell viability <70%) was observed at 2000 µM. Under the conditions of the ARE-Nrf2 Luciferase test the test substance did not induce luciferase activity in the transgenic KeratinoSens™ cell line.
c) Activation of dendritic cells
Dendritic cell response of the test substance was investigated in a human Cell Line Activation Test (h-CLAT) according to OECD Guideline 442E and in compliance with GLP. The doses for the main experiment were previously determined by two XTT tests. Cytotoxic effects were not observed following incubation with the test substance up to the highest soluble concentration of 250 μg/mL and thus a CV75 value could not be calculated. The viability of the cells in both XTT spaced within a range of 92.67% to 112.4% and 81.35% to 108.61%, respectively (threshold of cytotoxicity: < 75%).
In the main experiment test substance concentrations (solved in DMSO) of 84, 100, 121, 145, 174, 208, 250 and 300 µg/mL were administered to human THP-1 cells for 24 hours. Thereafter the cells were stained with FITC-labeled anti-CD86, CD54 antibody or mouse IgG1 (isotype control) and relative fluorescence intensity of the surface markers was measured in a flow cytometer. Since phase separation (oily droplets) was observed at the highest tested test item concentration (300 μg/mL), this concentration was excluded from the evaluation. Relative fluorescence intensity of CD86 and CD54 was greater than 150% and 200%, respectively in at least one dose in 2 out of 3 independent experiments. Therefore, the h-CLAT prediction for activation of dendritic cells is considered positive.
Conclusion
Based on a weight of evidence approach considering one positive and two negative results in the in vitro test battery according to the Adverse Outcome Pathway defined for skin sensitisation, the test substance is not considered to be a skin sensitiser.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The available data on skin sensitisation of the test substance do not meet the criteria for classification according to Regulation (EC) 1272/2008, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.